JoAnn Pinkerton, MD

An expert discussion with JoAnn Pinkerton, MD, national lead for the OASIS clinical trial program of elinzanetant for moderate-to-severe VMS.

JoAnn Pinkerton, MD, national lead for the OASIS clinical trial program evaluating elinzanetant for menopausal VMS, discusses how non-hormonal therapy differs from HRT.

Less than 15% of women in menopause receive treatment for VMS, suggesting a need a for more education and awareness, according to JoAnn Pinkerton, MD.

Building trust with patients early on will help them feel comfortable discussing their symptoms and treatment preferences, says JoAnn Pinkerton, MD.